Cargando…

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

Cyclin-dependent kinases (CDK) 4/6 inhibitors, namely abemaciclib, palbociclib, and ribociclib, interfere with cell cycle progression, induce cell senescence and might promote cancer cell disruption by a cytotoxic T cells-mediated effect. Phase III randomized clinical trials have proven that CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schettini, Francesco, De Santo, Irene, Rea, Carmen G., De Placido, Pietro, Formisano, Luigi, Giuliano, Mario, Arpino, Grazia, De Laurentiis, Michelino, Puglisi, Fabio, De Placido, Sabino, Del Mastro, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315195/ https://www.ncbi.nlm.nih.gov/pubmed/30631751 http://dx.doi.org/10.3389/fonc.2018.00608

Ejemplares similares

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer
por: Buonaiuto, Roberto, et al.
Publicado: (2022)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2020)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2017)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
por: Puglisi, Fabio, et al.
Publicado: (2021)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
por: De Placido, S, et al.
Publicado: (2017)

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
por: Gargiulo, Piera, et al.
Publicado: (2016)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
por: De Placido, Pietro, et al.
Publicado: (2022)

Prevalence of Sarcopenia in Women with Breast Cancer
por: Morlino, Delia, et al.
Publicado: (2022)

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
por: Buonaiuto, Roberto, et al.
Publicado: (2023)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
por: Servetto, Alberto, et al.
Publicado: (2021)

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
por: Rosa, Roberta, et al.
Publicado: (2013)

Immunological signature of patients with thymic epithelial tumors and Good syndrome
por: Malfitano, Anna Maria, et al.
Publicado: (2022)

Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
por: Pietroluongo, Erica, et al.
Publicado: (2023)

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
por: Cancello, Giuseppe, et al.
Publicado: (2008)

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
por: Crispo, Anna, et al.
Publicado: (2023)

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
por: Napolitano, Fabiana, et al.
Publicado: (2019)

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
por: Giuliano, Mario, et al.
Publicado: (2011)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
por: Lazzaro, Carlo, et al.
Publicado: (2013)

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature
por: Pensabene, Matilde, et al.
Publicado: (2018)

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
por: Caltavituro, Aldo, et al.
Publicado: (2023)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
por: Montella, Liliana, et al.
Publicado: (2022)

The European Reference Network: the keystone for the management of rare thoracic cancers
por: Morra, Rocco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i7p6nm9681lmf2odj06vlv4s1p